-
A new round of medical insurance negotiations is imminent, 19 rare disease drugs have passed the preliminary review, can the bargain be successful?
Time of Update: 2022-10-31
However, before the start of a new round of price negotiations, on October 12, the National Health Insurance Bureau responded to the relevant recommendation: a small number of particularly expensive rare disease drugs obviously exceed the basic medical insurance protection level, and cannot be included in the scope of medical insurance payment.
-
The valuation of pharmaceutical stocks has entered the bottom area, and the industry believes that there is great potential for upward revision
Time of Update: 2022-10-31
【Pharmaceutical Network Pharmaceutical Stock Market】News on October 26, the pharmaceutical sector strengthened, CRO, innovative drugs, devices and other subdivisions have strengthened, among which Pha
-
ResMed's New Product Launch Drives New Personalized Experiences in Sleep Breathing
Time of Update: 2022-10-31
Liu Ding, General Manager of ResMed China, said, "ResMed has been deeply engaged in the field of sleep and respiratory health for more than 30 years, and the release of this new product demonstrates ResMed's consistent philosophy of adhering to innovative research and development and insight into consumer health needs, which is of great significance to meet the customized needs of patients and explore the whole process of personalized services.
-
The highest price reduction was 94%, and the six major medical consumables began to be centrally purchased
Time of Update: 2022-10-31
Since then, the Shanxi Provincial Medical Insurance Bureau has guided each city to form three municipal alliances to carry out centralized procurement of low-value medical consumables on a regular basis.
-
Population aging accelerates China's artificial shoulder joint market has a lot of room for expansion
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; Recently, the Medical Device Technical Evaluation Center of the State Food and Drug Administration issued the "Guidelines for the Registration Review of Artificial Shoulder Joint Prosthesis (Draft for Comments)" to solicit comments from the public.
-
Complex formulations bring new growth points to the pharmaceutical industry: the market for dispensing systems will approach 2.2 billion in five years
Time of Update: 2022-10-31
At present, China's improved new drug industry has gradually entered a rapid development channel, and the overall market has shown rapid growth.
At present, China's improved new drug industry has gradually entered a rapid development channel, and the overall market has shown rapid growth.
-
With two consecutive years of price increases, how long can the lily high price period last?
Time of Update: 2022-10-31
In 2022, after the lily production is new, it will be reported that due to the impact of extreme weather, the mu yield will be greatly reduced, which has caused the production area and market popular
-
More than just Covid! American experts warn of this winter's "triple epidemic" storm
Time of Update: 2022-10-31
Centers for Disease According to reports, as of the afternoon of the 24th, the occupancy rate of pediatric beds in the United States reached the highest level in two years, and an estimated 75% of the 40,000 beds were pediatric patients.
-
Domestic enterprises have accelerated the layout of medical imaging equipment and conquered key core technologies
Time of Update: 2022-10-31
In order to better promote the development of medical imaging equipment in China, relevant enterprises also need to invest high in research and development and marketing, and continuously increase the development of the medical imaging equipment market.
-
Benchmarking more than $50 varieties, domestic new drugs "head-to-head" record shines!
Time of Update: 2022-10-31
In recent years, the sales trend of osimertinib in the six major markets of the three major terminals (10,000 yuan) Source: Intranet database What made osimertinib jump from the second line to the first line was a "head-to-head" FLAURA trial that directly compared the efficacy of erlotinib/gefitinib.
-
Over 10%! Sales of 98 brands of drugs over 100 million soared
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; According to the latest data from Intranet, the sales scale of terminal chemical drugs in public hospitals in key provinces and cities in the first half of 2022 exceeded 100 billion yuan, a slight decline from the same period last year.
-
The global field of PD-1/PD-L1 inhibitors is booming
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; Harnessing the body's immune system to fight cancer is one of the most remarkable achievements in the medical field of the past decade.
js?cdnversion='+~(-new Date()/36e5)]; Harnessing the body's immune system to fight cancer is one of the most remarkable achievements in the medical field of the past decade.
-
NMPA issued the Administrative Measures for Drug Recalls
Time of Update: 2022-10-31
Article 9: The State Medical Products Administration and the drug regulatory departments of provincial, autonomous regional, and directly governed municipality people's governments shall, in accordance with the relevant systems for drug information disclosure, employ effective channels to release to the public drug information and recall information with quality problems or other potential safety hazards, and when necessary, notify the competent health departments at the same level of relevant information.
-
Many pharmacies welcome the flight inspection! Do not step on these "minefields"
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; According to the official website of the Guangdong Provincial Food and Drug Administration, not long ago, Guangdong Province sent a total of 81 inspection teams to carry out unannounced inspections of 138 pharmaceutical wholesale enterprises and 76 pharmaceutical retail chain enterprises in the province by means of double randomization.
-
Pharmaceutical equipment companies have hit the IPO, the industry can be expected in spring?
Time of Update: 2022-10-31
Matt Technology is an enterprise mainly engaged in the research and development, design, production and sales of pharmaceutical equipment, the company intends to be listed on the main board of the Shanghai Stock Exchange, this public offering of 33.
-
Shanghai launches inhaled new crown vaccine booster vaccination The authoritative answer is here
Time of Update: 2022-10-31
According to the WeChat public account of the General Office of the Shanghai Municipal People's Government, on October 25, Shanghai launched the appointment registration for booster immunization of the recombinant new coronavirus vaccine (adenovirus vector type 5) for inhalation.
-
The pharmaceutical sector is optimistic, and many pharmaceutical stocks have been publicly offered in the third quarter
Time of Update: 2022-10-31
According to the disclosure of the performance of pharmaceutical companies in the third quarter of 2022, Wind data shows that as of October 26, a total of 141 A-share biopharmaceutical companies have disclosed their third quarterly reports, and nearly 60% of the company's net profit attributable to the parent in the first three quarters has increased year-on-year.
-
The medical device market began to repair, and the performance in the third quarter was outstanding
Time of Update: 2022-10-31
【Pharmaceutical Network Market Analysis】 Analysts pointed out that at present, under the encouragement of innovative medical devices, the marginal easing of centralized procurement policies, and the f
-
Under the "dual carbon" goal, there is still much room for improvement in the carbon reduction and emission reduction of pharmaceutical equipment
Time of Update: 2022-10-31
The application of carbon reduction and emission reduction technology of pharmaceutical equipment can greatly reduce the cost of raw materials and electrical energy in pharmaceutical production, as well as the cost of environmental protection, while avoiding environmental pollution problems, and helping to improve the production efficiency and economic benefits of pharmaceutical companies.
-
These medical insurance exclusive products have caught fire Simcere Pharmaceutical has soared more than 280 times
Time of Update: 2022-10-31
The latest news refers to the medical insurance negotiations in 2022 are expected to start in November, and who can finally be "insured" for 143 exclusive western drugs (including chemical drugs and
